Shareholders of Shanghai Bio-heart Biological Technology (HKG:2185) will meet Feb. 13 to vote on the proposed 155.6 million yuan capital injection into unit Zhejiang Bioheart Medical Equipment, a Thursday bourse filing said.
The parties had agreed on earlier in January that Jiaxing Guojian Baixin Equity Investment Partnership Enterprise would make the investment in exchange for a 45.3208% stake in Zhejiang Bioheart.
Price (HKD): $1.55, Change: $+0.010, Percent Change: +0.65%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.